TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has ...

Talisker Intersects 121.00 g/t Au over 1.00 m within 59.29 g/t Au over 2.10 metres, from the 2026 Bralorne Gold Project Resource Conversion Program

Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX:TSK | OTCQB:TSKFF) is pleased to announce results from the initial 25 drill holes from early 2026, predominantly targeting dip and strike ...